Gennex Laboratories Ltd

Gennex Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by a notable decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change comes against a backdrop of mixed sector performance and a challenging market environment, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Gennex Laboratories Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients and intermediates, reported consolidated net profit of ₹3.74 crores for Q4 FY26, marking a robust 61.21% year-on-year growth but a concerning 28.63% sequential decline. The Telangana-based company, with a market capitalisation of ₹285.00 crores, saw its stock retreat 4.42% to ₹11.25 following the results announcement, reflecting investor concerns over deteriorating operating margins despite impressive top-line expansion.

Gennex Laboratories Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended March 2026, with significant growth in profitability and revenue, despite a challenging market environment and a recent downgrade in its Mojo Grade to Sell.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price declines and underperformance relative to the Sensex, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling value compared to peers and historical averages.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Gennex Laboratories Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite ongoing challenges in its stock price performance relative to the broader market. This micro-cap pharmaceutical player’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling entry point compared to its historical averages and peer group benchmarks.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Gennex Laboratories Ltd has witnessed a notable improvement in its valuation parameters, shifting from very attractive to attractive territory, driven primarily by a subdued price-to-earnings (P/E) ratio and price-to-book value (P/BV) metrics. Despite this positive valuation shift, the company’s stock performance over recent months and years presents a mixed picture when compared to broader market benchmarks such as the Sensex.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into its performance and outlook.

Gennex Laboratories Ltd’s share price declined to a fresh 52-week low of ₹7.1 on 30 March 2026, marking a significant downturn for the pharmaceutical and biotechnology company amid broader market weakness and persistent underperformance relative to benchmarks.

Gennex Laboratories Ltd’s share price declined to a fresh 52-week low of ₹7.87 on 27 March 2026, marking a significant drop amid broader market weakness and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Despite a broad market upswing, Gennex Laboratories Ltd has slipped to a fresh 52-week low of Rs 8.06 on 25 Mar 2026, marking a near 53% decline from its 52-week high of Rs 17.25. This divergence from the market rally highlights persistent headwinds for the micro-cap pharmaceutical player.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with the latest insights into the company’s performance and outlook.